ArticleVirology journal2025
Exploring the challenge of diagnosing and tracking Oropouche virus during Brazil's largest recorded dengue epidemic in 2024.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Oropouche Virus (OROV) Vaccine Development for Vulnerable Populations: Epidemiological Context, Challenges and Future Directions.Vaccines · 2026Review
- Ten years of Zika in Brazil: achievements, challenges and perspectives.Virology journal · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2024, Brazil experienced its largest dengue virus (DENV) epidemic alongside the widest spread of Oropouche virus (OROV) to date. This scenario may have strongly impacted public health surveillance efforts, as DENV and OROV infections often lead to similar clinical signs and symptoms, making clinical differential diagnosis challenging. Herein, we investigated whether the co-circulation of DENV and OROV in Brazil in 2024 may have hampered OROV detection and tracking, potentially contributing to possible underdiagnosis.
methodsThe number of confirmed cases of dengue and Oropouche in 2024, as well as the probable states of infection, were collected on June 9, 2025, from the Brazilian Ministry of Health database. For dengue, cases were analyzed according to the diagnostic approach: laboratory testing or diagnosis by clinical-epidemiological criteria. All Oropouche cases considered here were confirmed by laboratory testing. Finally, dengue and Oropouche cases were grouped by state and epidemiological week, and their temporal-spatial overlap was assessed to discuss its potential negative effect on OROV reporting.
resultsA total of 5,956,257 dengue cases were recorded in Brazil, of which only 2,191,326 were laboratory confirmed. All states, including the Federal District, registered dengue cases, with highest number in São Paulo and Minas Gerais states (Southeast region). Dengue peaks occurred in early 2024 for Brazil overall and for individual states. Regarding Oropouche, 13,856 cases were recorded in 22 states, the majority in Espírito Santo (Southeast region) and Amazonas (North region). Oropouche cases in Brazil (total cases) showed two peaks: a smaller one at the beginning of 2024 and a higher one at the end of the year. On the other hand, OROV peaked in different periods depending on the state analyzed. In general, Oropouche cases were described close to the dengue reporting period, mainly in Amazonas, Pará and Rondônia states (northern Brazil), where there was evident overlap between the dengue and Oropouche curves.
conclusionDENV and OROV co-circulated in most of Brazil in 2024. Furthermore, most dengue diagnoses were based on clinical-epidemiological criteria. This approach, combined with the clinical and temporal-spatial overlap between dengue and Oropouche cases, may have contributed to misdiagnoses, potentially hindering OROV detection and tracking. These findings reinforce the importance of laboratory testing for accurate arbovirus identification and surveillance in Brazil.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.